{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:57:23Z","timestamp":1787003843152,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44391-x","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:51:27Z","timestamp":1774007487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaccine-derived T-cell responses are insufficient to generate protective immunity to SARS-CoV-2"],"prefix":"10.1038","volume":"16","author":[{"given":"Soung-Chul","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon J.","family":"Szymura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmol","family":"Kandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"44391_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41423-023-01104-y","volume":"21","author":"BL Sievers","year":"2024","unstructured":"Sievers, B. L., Cheng, M. T. K., Csiba, K., Meng, B. & Gupta, R. K. SARS-CoV-2 and innate immunity: the good, the bad, and the goldilocks. Cell. Mol. Immunol. 21, 171\u2013183. https:\/\/doi.org\/10.1038\/s41423-023-01104-y (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"44391_CR2","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.1038\/s41467-023-43447-0","volume":"14","author":"KL Hilligan","year":"2023","unstructured":"Hilligan, K. L. et al. Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2. Nat. Commun. 14, 8229. https:\/\/doi.org\/10.1038\/s41467-023-43447-0 (2023).","journal-title":"Nat. Commun."},{"key":"44391_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"44391_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634. https:\/\/doi.org\/10.1038\/s41586-020-03041-6 (2021).","journal-title":"Nature"},{"key":"44391_CR5","doi-asserted-by":"publisher","first-page":"100204","DOI":"10.1016\/j.xcrm.2021.100204","volume":"2","author":"A Tarke","year":"2021","unstructured":"Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell. Rep. Med. 2, 100204. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100204 (2021).","journal-title":"Cell. Rep. Med."},{"key":"44391_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880. https:\/\/doi.org\/10.1016\/j.cell.2021.01.007 (2021).","journal-title":"Cell"},{"key":"44391_CR7","doi-asserted-by":"publisher","unstructured":"Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489\u20131501 e1415, (2020). https:\/\/doi.org\/10.1016\/j.cell.2020.05.015","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"44391_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","volume":"399","author":"A Khobragade","year":"2022","unstructured":"Khobragade, A. et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399, 1313\u20131321. https:\/\/doi.org\/10.1016\/S0140-6736(22)00151-9 (2022).","journal-title":"Lancet"},{"key":"44391_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/6995","volume":"17","author":"A Biragyn","year":"1999","unstructured":"Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. & Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17, 253\u2013258. https:\/\/doi.org\/10.1038\/6995 (1999).","journal-title":"Nat. Biotechnol."},{"key":"44391_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1126\/science.1075565","volume":"298","author":"A Biragyn","year":"2002","unstructured":"Biragyn, A. et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 1025\u20131029. https:\/\/doi.org\/10.1126\/science.1075565 (2002).","journal-title":"Science"},{"key":"44391_CR11","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1182\/blood-2009-05-219683","volume":"114","author":"H Qin","year":"2009","unstructured":"Qin, H. et al. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 114, 4142\u20134149. https:\/\/doi.org\/10.1182\/blood-2009-05-219683 (2009).","journal-title":"Blood"},{"key":"44391_CR12","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.4049\/jimmunol.167.11.6644","volume":"167","author":"A Biragyn","year":"2001","unstructured":"Biragyn, A. et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167, 6644\u20136653 (2001).","journal-title":"J. Immunol."},{"key":"44391_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12885-018-4094-2","volume":"18","author":"SK Thomas","year":"2018","unstructured":"Thomas, S. K. et al. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer. 18, 187. https:\/\/doi.org\/10.1186\/s12885-018-4094-2 (2018).","journal-title":"BMC Cancer"},{"key":"44391_CR14","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2005-08-3207","volume":"107","author":"R Schiavo","year":"2006","unstructured":"Schiavo, R. et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8\u2009+\u2009T-cell responses. Blood 107, 4597\u20134605. https:\/\/doi.org\/10.1182\/blood-2005-08-3207 (2006).","journal-title":"Blood"},{"key":"44391_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269. https:\/\/doi.org\/10.1038\/s41586-020-2008-3 (2020).","journal-title":"Nature"},{"key":"44391_CR16","doi-asserted-by":"publisher","unstructured":"Crawford, K. H. D. et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 12, (2020). https:\/\/doi.org\/10.3390\/v12050513","DOI":"10.3390\/v12050513"},{"key":"44391_CR17","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","volume":"11","author":"F Chiuppesi","year":"2020","unstructured":"Chiuppesi, F. et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat. Commun. 11, 6121. https:\/\/doi.org\/10.1038\/s41467-020-19819-1 (2020).","journal-title":"Nat. Commun."},{"key":"44391_CR19","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 3, e52\u2013e61. https:\/\/doi.org\/10.1016\/S2666-5247(21)00267-6 (2022).","journal-title":"Lancet Microbe"},{"key":"44391_CR20","doi-asserted-by":"publisher","first-page":"e0040421","DOI":"10.1128\/JVI.00404-21","volume":"95","author":"SJ Vidal","year":"2021","unstructured":"Vidal, S. J. et al. Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. J. Virol. 95, e0040421. https:\/\/doi.org\/10.1128\/JVI.00404-21 (2021).","journal-title":"J. Virol."},{"key":"44391_CR21","doi-asserted-by":"publisher","first-page":"eabl4509","DOI":"10.1126\/sciimmunol.abl4509","volume":"6","author":"B Israelow","year":"2021","unstructured":"Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci. Immunol. 6, eabl4509. https:\/\/doi.org\/10.1126\/sciimmunol.abl4509 (2021).","journal-title":"Sci. Immunol."},{"key":"44391_CR22","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin, M. J. et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl. J. Med. 386, 2188\u20132200. https:\/\/doi.org\/10.1056\/NEJMoa2116620 (2022).","journal-title":"N Engl. J. Med."},{"key":"44391_CR23","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.16525","volume":"61","author":"JW Senefeld","year":"2021","unstructured":"Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 61, 2503\u20132511. https:\/\/doi.org\/10.1111\/trf.16525 (2021).","journal-title":"Transfusion"},{"key":"44391_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","volume":"603","author":"R Keeton","year":"2022","unstructured":"Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488\u2013492. https:\/\/doi.org\/10.1038\/s41586-022-04460-3 (2022).","journal-title":"Nature"},{"key":"44391_CR25","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1093\/cid\/ciab954","volume":"75","author":"N Madelon","year":"2022","unstructured":"Madelon, N. et al. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study. Clin. Infect. Dis. 75, e1037\u2013e1045. https:\/\/doi.org\/10.1093\/cid\/ciab954 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"44391_CR26","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","volume":"5","author":"C Perry","year":"2021","unstructured":"Perry, C. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 5, 3053\u20133061. https:\/\/doi.org\/10.1182\/bloodadvances.2021005094 (2021).","journal-title":"Blood Adv."},{"key":"44391_CR27","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137, 3165\u20133173. https:\/\/doi.org\/10.1182\/blood.2021011568 (2021).","journal-title":"Blood"},{"key":"44391_CR28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811. https:\/\/doi.org\/10.1126\/science.abc6284 (2020).","journal-title":"Science"},{"key":"44391_CR29","doi-asserted-by":"publisher","first-page":"e0009374","DOI":"10.1371\/journal.pntd.0009374","volume":"15","author":"KM Chai","year":"2021","unstructured":"Chai, K. M. et al. DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss. PLoS Negl. Trop. Dis. 15, e0009374. https:\/\/doi.org\/10.1371\/journal.pntd.0009374 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"44391_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41541-021-00384-7","volume":"6","author":"VM Andrade","year":"2021","unstructured":"Andrade, V. M. et al. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. NPJ Vaccines. 6, 121. https:\/\/doi.org\/10.1038\/s41541-021-00384-7 (2021).","journal-title":"NPJ Vaccines"},{"key":"44391_CR31","doi-asserted-by":"publisher","first-page":"1292059","DOI":"10.3389\/fimmu.2024.1292059","volume":"15","author":"JT Gordy","year":"2024","unstructured":"Gordy, J. T. et al. A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3alpha elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses. Front. Immunol. 15, 1292059. https:\/\/doi.org\/10.3389\/fimmu.2024.1292059 (2024).","journal-title":"Front. Immunol."},{"key":"44391_CR32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507 (2020).","journal-title":"Science"},{"key":"44391_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.30.125484","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes. bioRxiv https:\/\/doi.org\/10.1101\/2020.05.30.125484 (2020).","journal-title":"bioRxiv"},{"key":"44391_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372. https:\/\/doi.org\/10.1038\/s41467-020-20653-8 (2021).","journal-title":"Nat. Commun."},{"key":"44391_CR35","doi-asserted-by":"publisher","unstructured":"Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432\u20135447 e5416, (2021). https:\/\/doi.org\/10.1016\/j.cell.2021.09.015","DOI":"10.1016\/j.cell.2021.09.015"},{"key":"44391_CR36","doi-asserted-by":"publisher","unstructured":"Shi, J. et al. A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies. JCI Insight. 9 https:\/\/doi.org\/10.1172\/jci.insight.155789 (2024).","DOI":"10.1172\/jci.insight.155789"},{"key":"44391_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243 (2018).","journal-title":"Nat. Rev. Drug Discov"},{"key":"44391_CR38","doi-asserted-by":"publisher","first-page":"eadu6730","DOI":"10.1126\/sciimmunol.adu6730","volume":"10","author":"K Kocher","year":"2025","unstructured":"Kocher, K. et al. Vaccination-induced T cell responses maintain polyclonality with high antigen receptor avidity. Sci. Immunol. 10, eadu6730. https:\/\/doi.org\/10.1126\/sciimmunol.adu6730 (2025).","journal-title":"Sci. Immunol."},{"key":"44391_CR39","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.4049\/jimmunol.158.9.4129","volume":"158","author":"WJ Karpus","year":"1997","unstructured":"Karpus, W. J. et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J. Immunol. 158, 4129\u20134136 (1997).","journal-title":"J. Immunol."},{"key":"44391_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/35006097","volume":"404","author":"L Gu","year":"2000","unstructured":"Gu, L. et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404, 407\u2013411. https:\/\/doi.org\/10.1038\/35006097 (2000).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44391-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:02:05Z","timestamp":1778338925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44391-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44391"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44391-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8158863\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14331"}}